Prostate Cancer Advisor Videos - Renal and Urology News

Prostate Cancer Advisor Videos

Chapter 1

Targeted Treatment with Abiraterone and Enzalutamide (Cont)

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Chapter 2

Appropriate Candidates for Intermittent ADT

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal duration of androgen deprivation in the treatment of high-risk and very high-risk locally advanced prostate cancer.

Chapter 3

Radium-223: Patient Selection and Timing of Treatment

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 4

The Future: DNA Repair Defects, Immune Checkpoint Inhibitors

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss their predictions for advances in the treatment of men with prostate cancer in next 5 years.

Chapter 5

Appropriate Candidates for ADT + Radiation

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of radiation with androgen deprivation therapy in men with prostate cancer.

Chapter 6

Mechanisms of ADT Resistance

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss resistance to androgen deprivation therapy in men with prostate cancer.

Chapter 7

Docetaxel in Combination with Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of docetaxel in combination with androgen deprivation therapy in men with prostate cancer.

Chapter 8

Matching Treatment Sequences to Specific Patients

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal sequencing of therapies in metastatic castration resistant prostate cancer.

Chapter 10

The Role of Cabazitaxel and Docetaxel in mCRPC

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the role of cytotoxic chemotherapy in treatment of castration resistant prostate cancer and metastatic castration resistant prostate cancer.

Chapter 11

Trigger Points for Starting Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss androgen deprivation therapy in advanced/metastatic prostate cancer.

Chapter 12

Targeted Treatment with Abiraterone and Enzalutamide

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.